Maxim Group reaffirmed their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $22.50 target price on the stock.
Palisade Bio Stock Performance
NASDAQ PALI opened at $7.08 on Wednesday. The firm has a 50-day moving average of $5.70 and a 200-day moving average of $7.47. Palisade Bio has a 52-week low of $3.82 and a 52-week high of $36.60.
Palisade Bio (NASDAQ:PALI – Get Free Report) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($3.75) earnings per share for the quarter. As a group, sell-side analysts expect that Palisade Bio will post -12.29 earnings per share for the current year.
About Palisade Bio
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.
Featured Articles
- Five stocks we like better than Palisade Bio
- What is a Secondary Public Offering? What Investors Need to Know
- Kraft Heinz: Serving Up A Tasty Dip for Investors to Snack On
- ETF Screener: Uses and Step-by-Step Guide
- Yum! Brands: Can Digital Strength Offset Same-Store Declines?
- The 3 Best Blue-Chip Stocks to Buy Now
- Wall Street Believes in First Solar Stock’s Bull Cycle
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
